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Clinical and metabolic profile
of HIV-positive patients
with lipodistrophy
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ABSTRACT
Study Design: Descriptive Study
Objective: To evaluate the clinical and metabolic profile of HIV-seropositive patients on HAART with a
diagnosis of associated lipodystrophy. Methods: We analyzed data computed in a protocol attached to
the records of patients treated at the University Hospital of the Medical School of Ribeirão Preto. Results:
69.7% of the participants were male. Mean ± standard deviation body mass index was 24.7 ± 3.6 kg/m2
and 26.7 ± 5.98 kg/m2, and average weight 72.78 ± 12.7 kg and 65.94 ± 15.4 kg for males and females,
respectively. The percentage of lean mass was greater in men (p = 0.0008) and body fat was greater in
women (p = 0.0006). Median total cholesterol was 235 mg/dl and median triglycerides were 387 mg/dl.
Fifty percent of the patients had abdominal lipohypertrophy, 27.9% facial lipoatrophy, and 12.5% cervical
lipohypertrophy. Conclusion: Clinical and metabolic changes were detected, which represent additional
risk factors for the occurrence of coronary diseases in these patients.
Keywords: Patients/metabolism. Lipodystrophy.  Antiretroviral Therapy, Highly Active. HIV. HIV-Associated
Lipodystrophy Syndrome. Cardiovascular Diseases.
Introduction
Acquired immunodeficiency syndrome (AIDS)
was first detected in the 1980's after the discovery
and definition of the first cases in the U.S., Haiti and
Central Africa. Originally limited to specific areas, the
syndrome quickly spread to various regions of the
world, becoming a pandemic.1
According to the Joint United Nations Pro-
gramme on HIV/AIDS annual report, more than 33
million people are currently living with HIV/AIDS in
the world. In Brazil, 474,273 cases were notified from
1980 to June 2007.2
The infection natural course is characterized by
intense and continuous viral replication resulting in the
destruction of CD4+ cells (lymphocyte cells responsi-
88
Medicina (Ribeirão Preto) 2011;44(1): 87-93
http://www.fmrp.usp.br/revista
Falcato RG,  Monteiro JP, Machado AA, Navarro AM.
Perfil de pacientes HIV positivo com lipodistrofia
ble for the recognition of antigens foreign to the or-
ganism) which, with other immune system changes,
leads to immunodeficiency. The suppression of T4
lymphocytes or T helper cells characterizes an immu-
nosuppressive reaction's final stage that leads the or-
ganism to be highly susceptible to the development of
tumors and opportunistic infections.3
The first drug used for the HIV-seropositive
treatment was Zidovudin, a medication originally used
by patients with cancer which was able to reduce vi-
ral replication.2 Drug treatment evolved with the first
protease inhibitors (PI) and the nucleoside-analogue
reverse transcriptase inhibitors (NRTI) or non-nucle-
oside (NNRTI) development, followed by the discov-
ery that drug combination was more effective in re-
ducing the progression of infection. This finding led a
new anti-HIV therapy proposal, the Highly Active
Antiretroviral Therapy (HAART),4 which consists of
a therapeutic drugs combination, including PI class and
NRTI or NNRTI.5
The HAART use promotes a significant viral
replication suppression and reduces the opportunistic
infections occurrence, thus also reducing morbidity and
mortality.6,7 However, the use of antiretroviral therapy
is accompanied by severe side effects including clini-
cal and metabolic changes such as peripheral
lipoatrophy, central lipohypertrophy, body fat redistri-
bution, dyslipidemia, insulin resistance, and changes in
glucose metabolism. The set of these alterations is
known as HIV lipodystrophy syndrome (HIVLS).1,3,4
The mechanisms responsible for metabolism and
body composition's abnormalities have not been well
defined.8 These changes increase the risk of hyper-
triglyceridemia's complications and psychological dis-
orders, in addition to accelerating the occurrence of
atherosclerosis and cardiovascular diseases (CVD) due
to HIV infection and/or antiretroviral treatment.9,10
The nutritional study of HIV-seropositive per-
sons is directly related to the disease's prognosis.11
Studies assessing the HIV-positive patients' metabolic
profile at the beginning of or even during treatment
are important for an appropriate diagnosis and nutri-
tional intervention, in order to improve the life quality
and life expectancy of treated subjects.
Thus, the objective of the present investigation
was to assess the clinical and metabolic profile of HIV-
positive patients on HAART with associated lipodys-
trophy diagnosis, based on personal, clinical and fam-
ily history of these individuals, besides the analysis of
characteristics physical HIVLS signs and the evalua-
tion of their lipid and glycemic profile.
Methods
The study was conducted at the Special Unit
for the Treatment of Infectious Diseases (UETDI),
Dyslipidemia Outpatient Clinic (ADIS), of the Uni-
versity Hospital, Faculty of Medicine of Ribeirão Preto
(HC-FMRP).
The selected study group was consisted in HIV-
seropositive patients of both sexes, aged 20 years or
older, attended at ADIS from January 2003 to August
2009, with different viral loads and in different dis-
ease stages, receiving HAART and with a diagnosis
of dyslipidemia.
Data collection was organized based on a ques-
tionnaire regarding personal data, including lifestyle,
presence of chronic non-communicable diseases
(CNCD), dyslipidemia classification, HAART drug
class; family history of CNCD; anthropometric data,
including weight, height, abdominal circumference,
skinfolds and electrical bioimpedance; physical exami-
nation to evaluate fat distribution and malnutrition signs;
and lipid and glucose laboratory exams. The answers,
excepted for anthropometric and laboratory data, were
given as "yes", "no" or "unknown/ignored".
These data were collected at the first visit, by
the professionals responsible for routine care and added
to the patient's medical records. Thus, this was a ret-
rospective study based on the collection of this infor-
mation from medical records of the patient.
The lipidogram and glycemia analyses were
based on the laboratory data provided by the Central
Laboratory of HC-FMRP. The IV Brazilian Directive
for Dyslipidemia and the Prevention of Atherosclero-
sis were used as reference values for the evaluation
of the biochemical parameters.12
The project was approved by the Research Eth-
ics Committee of HCRP and FMRP-USP on March
16, 2009 (Protocol no. 13149/2008).
Data analysis
The Epidata® software (version 3.1)13 was
used to organize data for the data bank construction.
The data were analyzed statistically using the StatSoft
Inc.® (1996)14 and EpiData Analysis® (version 2.
2.1.171) software. The Microsoft Office Excel 2007®
software was used to construct graphs and tables.
Variables were analyzed statistically using the
Kruskal-Wallis test, with the level of significance set
at p < 0.05.
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Results
A total of 120 questionnaires were collected
from patients attended at ADIS-HC-FMRP during the
period established by research. Only one of them was
discarded due to the presence of pregnancy by the
time of data collection.
Most of the 119 participants were males
(69.7%). Mean (± SD) age and weight differed sig-
nificantly between sexes (Table 1).
Another anthropometric parameter analysis re-
vealed an average abdominal circumference of 92.2
± 14.69 cm for men and 92.9 ± 12.39 cm for women.
Lean mass and body fat percentage differed signifi-
cantly between men and women, whereas total body
water percentage was similar for the two groups (Fig-
ure I).
Table 2 presents the median, minimum and
maximum values of resistance, reactance, lean mass,
body fat and total body water, determined by electri-
cal bio-impedance.
 Smoking, alcohol drinking and sedentary per-
centages detected in the study population was 19.7%,
24.3% and 63.7%, respectively.
According to previous knowledge of the patients,
diabetes mellitus (DM) was present in 9.4% of them
and systemic arterial hypertension (SAH) in 22.3%.
Figure 2 illustrates the distribution of CNCD
among patients' relatives as reported by the patients.
On average, 5.7% of them reported not know how to
answer such questions (unknown/ignored) (Figure 2).
Table 3 presents the biochemical data collected.
Median total cholesterol was 235 mg/dl (range: 115-
889 mg/dl). Median triglyceride (TG) level was 387
mg/dl (range: 76-3278 mg/dl).
Table 1
Distribution of age, BMI and weight by sex. Data are reported as mean + SD
Sex N Mean SD CI (95%) P value
Age (years) Male 81 43.12 ±8.08 41.34 44.91 0.007
Female 35 48.17 ±10.61 44.53 51.82
BMI (kg/m2) Male 82 24.77 ±3.6 23.98 25.56 0.06
Female 34 26.79 ±5.98 24.71 28.88
Weigth (kg) Male 83 72.78 ±12.7 70.01 75.56 0.003
Female 34 65.94 ±15.4 60.57 71.31
 
Figure 1: Mean + SD values of waist circumference, lean mass, fat mass and total body water by sex.
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Table 2
Results of bioelectrical impedance by percentile
Parameters N Min p5 Median p95 Max
Resistance 40 50 274.2 510 742.85 883
Reactance 39 39 49 61 159 426
Lean mass (%) 28 59 59 73.5 85.55 86
Fat mass (%) 28 13 13.45 24 40 40
Total body water (%) 27 27 33.4 55 68.6 73
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Figure 2: Family history of chronic diseases.
Table 3
Distribution of biochemical parameters by percentile
Parameters N Min p5 Median p95 Max
Total cholesterol 115 115 134.6 235 383.4 889
Triglyceride 116 76 146.85 387 1157.65 3278
LDL cholesterol 48 20 33.7 133.5 252 296
HDL-c (males) 69 18 23 35 62 79
HDL-c (females) 29 25 25 39 55 59
Glucose 72 74 81 96.5 192.65 277
Total cholesterol higher than 200 mg/dl percent-
age was 72.4%. 95.3% of the participants had serum
TG levels above reference value (150 mg/dl), and
43.1% had glycemia levels higher than 100 mg/dl.
When the presence of hyperlipidemia or hyper-
glycemia was evaluated according to time of HAART
use, no significant difference was detected between
time of use and the parameters assessed (Figure 3).
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Occurrence of lipodystrophy analysis demon-
strated that 50% of the patients had abdominal lipo-
hypertrophy, 27.9% had facial lipoatrophy, and 12.5%
cervical lipohypertrophy.
Discussion
The present study demonstrated that most of
the patients at ADIS-HC-FMRP were male with a
lower average age than women (p = 0.007). Anthro-
pometric patients' data analysis revealed that, based
on body mass index (BMI), most men were eutrophic
and most women overweight. Among women, aver-
age abdominal circumference was higher than refer-
ence borderline value (> 88 cm) defined for an in-
creased risk to develop CVD.15,16
Bioelectrical impedance data indicated a greater
lean mass percentage among males and a greater
amount of body fat among women. The difference in
body composition between the sexes is classically found
in the general population17 (values of total body fat
between 8-24% for men and 21-35% for women are
acceptable18). So, it is observed in this study that body
composition matches with pacient's nutritional status
classification.
In relation to cigarette smoking, according to
the IV Brazilian Directive for Dyslipidemia and the
Prevention of Atherosclerosis of the Brazilian Cardi-
ology Society (2007),12 recent studies have reported
a 17% rate of cigarette smoking people, a lower preva-
lence than that observed among today's patients.
Average DM prevalence detected here was within
the range determined by the 1980 National Diabetes
Census (from 5 to 10%), but it was above national mean
(9.4% versus 7.6%). Regarding SAH, according to
1991 IBGE data,12 the prevalence of SAH was close
to, but lower than, the average for the state of São
Paulo (25%). It should be pointed out that in the present
study, these data weren't checked by exams, but were
reported by the patients themselves, a fact that might
have underestimated the real number of carriers.
High percentage of CNCD among patients' rela-
tives suggests an increased risk of developing these
diseases since the genetic component represents a risk
factor for these diseases that cannot be modified.16
Hyperlipidemia signs and symptoms were evi-
dent among participants since this was the determi-
nant factor for patients to be seen at the ADIS. How-
ever, very high levels of both TG and cholesterol were
detected. High level of TG increases the risk of de-
veloping pancreatitis and other complications,9 and
hypercholesterolemia is directly associated with the
risk of coronary disease.19
LDL cholesterol levels were evaluated but not
analyzed, because it is known that when associated
with TG levels higher than 200 mg/dl, VLDL levels
are increased in a different manner and the concen-
tration of LDL cholesterol is less related to VLDL
and LDL (non-HDL) levels.16
Regarding glucose changes, cross-sectional
studies have reported a 3-17% prevalence of sympto-
matic hyperglycemia among individuals treated with
PI.20 In the present study, there was a 43% preva-
lence of glycemia levels higher than 100 mg/dl, how-
ever, the group was not analyzed according to type of
antiretroviral therapy.
According to Friis-Moller (2003), patients ex-
posed to antiretroviral therapy for a longer period of
time tend to present a greater prevalence of lipodys-
trophy.21 Analysis of the relation between hyperlipi-
demia or hyperglycemia and the time of HAART did
not show a significant difference, probably due to the
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Figure 3: Distribution of biochemical parameters according to time of HAART.
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wide variability of the biochemical values detected
during each interval. Variations detected in these bio-
chemical results may have been due to whether or not
the individuals were taking hypolipemiant and/or
hypoglycemiant drugs before data collection.
In a prospective study cited by Qaqish et al
(2000), women receiving HAART developed lipodys-
trophy within an average period of one year. Of these,
90% presented abdominal lipohypertrophy, 38% facial
lipoatrophy, and 19% dorsocervical lipohypertrophy.22
In the present study, the occurrence of these three
types of lipodystrophy was 50%, 27.9% and 12.5%,
respectively. In both studies, such changes were de-
tected by physical examination, although the former
study also used bioelectrical impedance and anthropo-
metric measurements, a fact that may have increased
the sensitivity of the detection of these changes.
Conclusion
HIV-seropositive patients on antiretroviral treat-
ment are at increased risk to develop CVD due to the
virus itself and to the use of HAART.
The present study detected additional risk fac-
tors for coronary diseases occurrence, such as body
composition, DM, SAH, hereditary influence, smok-
ing habit, alcohol drinking, sedentary, as well as changes
in the lipidogram and glycemia in these patients.
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RESUMO
Modelo do Estudo: Estudo descritivo
Objetivo: Avaliar o perfil clínico e metabólico dos pacientes soropositivo para HIV, em uso de terapia anti-
retroviral fortemente ativa (Highly Active Antiretroviral Therapy - HAART) e com diagnóstico de lipodistrofia
associada. Métodos: A pesquisa foi realizada a partir da análise de dados computados em um protoco-
lo anexado ao prontuário de pacientes atendidos na Unidade Especial de Tratamento para Doenças
Infecciosas (UETDI), no Ambulatório de Dislipidemia (ADIS) do Hospital das Clínicas da Faculdade de
Medicina de Ribeirão Preto (HC-FMRP). Resultados: 69,7% dos participantes eram do sexo masculino.
As médias (DP) de IMC foram 24,7±3.6 Kg/m2 e 26,7 ±5.98 Kg/m2 e média de peso 72,78±12.7 Kg e
65,94±15.4 Kg para o sexo masculino e feminino, respectivamente. A porcentagem de massa magra foi
maior nos homens (p=0,0008) e de gordura corporal, maior no sexo oposto (p=0,0006). A variação do
colesterol total teve mediana igual a 235mg/dl e os triglicérides, mediana de 387mg/dl. A ocorrência de
lipodistrofia demonstrou que 50% dos pacientes apresentaram lipohipertrofia abdominal, 27,9%
lipoatrofia facial e 12,5% lipohipertrofia cervical. Conclusão: Alterações clínicas e metabólicas foram
encontradas, o que representa fatores de risco adicionais para a ocorrência de doenças coronarianas
nestes pacientes.
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